BlackRock Investment Management’s Alder Biopharmaceuticals ALDR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q4
$3.8M Sell
182,686
-5,984
-3% -$156K ﹤0.01% 1779
2016
Q3
$6.18M Buy
188,670
+1,610
+0.9% +$49K 0.01% 1335
2016
Q2
$4.67M Buy
187,060
+93,980
+101% +$2.54M 0.01% 1480
2016
Q1
$2.28M Sell
93,080
-16,745
-15% -$388K ﹤0.01% 1899
2015
Q4
$3.63M Buy
109,825
+1,008
+0.9% +$34.1K ﹤0.01% 1624
2015
Q3
$3.56M Buy
108,817
+1,519
+1% +$64.6K ﹤0.01% 1620
2015
Q2
$5.68M Buy
107,298
+42,441
+65% +$1.54M 0.01% 1400
2015
Q1
$1.87M Buy
64,857
+24,677
+61% +$677K ﹤0.01% 2073
2014
Q4
$1.17M Buy
40,180
+480
+1% +$8.62K ﹤0.01% 2440
2014
Q3
$503K Buy
39,700
+115
+0.3% +$1.74K ﹤0.01% 2973
2014
Q2
$794K Buy
+39,585
New +$557K ﹤0.01% 2777

Other funds holding ALDR

BlackRock Investment Management's ALDR Position: Q4 2016 in Review

BlackRock Investment Management reduced its Alder Biopharmaceuticals (ALDR) stake by 3.2% in Q4 2016, selling an estimated $156K and leaving 182,686 shares worth $3.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1779.

BlackRock Investment Management first reported a position in ALDR in Q2 2014 and has held it in 11 quarters since. The position peaked at $6.18M in Q3 2016. 145 funds tracked by Wall St. Rank hold ALDR as of Q4 2016.

  • BlackRock Investment Management held 182,686 shares of Alder Biopharmaceuticals worth $3.8M as of Q4 2016.
  • BlackRock Investment Management sold 5,984 Alder Biopharmaceuticals shares in Q4 2016, an estimated $156K.
  • Alder Biopharmaceuticals made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #1779 holding.
  • BlackRock Investment Management first reported a position in Alder Biopharmaceuticals in Q2 2014 and has held it in 11 quarters since.
  • BlackRock Investment Management's Alder Biopharmaceuticals position peaked at $6.18M in Q3 2016.
  • 145 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.